Intergama 2025: Rent Still Funds the Story, but the Center of Gravity Has Shifted to Urban Renewal

Getting to Know the Company

Intergama is no longer read correctly as a small listed landlord with two income-producing assets and a bit of development optionality on the side. That description used to be close enough. By 2025 it is already too partial. Yes, the operating base still rests on two wholly owned assets in Herzliya and Netanya, which together generate NIS 19.27 million of revenue, NIS 14.01 million of NOI and extremely low leverage at just 4% LTV. But anyone reading the company only through current rent is missing the main point, the upside and the risk are both moving toward the Sheret and Bazel urban-renewal projects and, after the balance sheet date, toward the Dankner Kanlov acquisition as well.

What is working now? The income-producing assets still provide a stable base, equity stands at NIS 258.4 million, the Netanya asset is unencumbered, and Sheret is already in an advanced execution phase. Why does that matter now? Because the company is trying to turn a relatively conservative small-portfolio structure into a broader urban-renewal platform. Why is the story still not clean? Because future profit from the projects is further out, more financing-intensive, and sits partly above the common-shareholder layer. What would have to happen for the read to improve? The new acquisition needs to be funded without squeezing flexibility, Sheret and Bazel need to keep selling and executing, and occupancy and rent quality in Netanya need to stabilize in a more convincing way.

There is also a practical actionability constraint here. The current market cap is around NIS 142.9 million, but the last daily trading turnover was just NIS 2,100. This is an extremely illiquid stock. Even if the business thesis improves, the market's ability to reprice it quickly or deeply remains limited.

The economic map looks like this:

What the first read is likely to miss:

• The swing from loss to profit in residential activity looks sharper than it really is, because the 2024 base was weakened retroactively by the application of Staff Position 11-6, which turned a NIS 767 thousand profit at the held-company level into a NIS 260 thousand loss.
• Real-estate values did not improve across the board. Netanya rose to NIS 186.2 million, but Herzliya fell to NIS 101.4 million after the company moved to a standalone planning route at FAR 8 rather than relying on a joint-lot scenario.
• Part of the reported property value rests on licensing assumptions. In Herzliya the appraiser assumes 746 square meters built without a permit can be regularized, and in Netanya the valuation includes the regularization of 1,360 square meters of storage converted from parking.
• The residential projects produce attractive 100% numbers, but only a much smaller share, roughly one sixth of each project, belongs economically to the listed company, and only after time, financing and project-level obligations.

Events and Triggers

The small accounting change behind the bigger headline

The first trigger is not operational at all, but accounting. Staff Position 11-6 on urban renewal was applied retroactively, and in practice cut the company's share of equity-accounted profit in 2024 by NIS 1.027 million. So anyone looking only at the move from a NIS 260 thousand loss to NIS 1.684 million profit in residential activity is seeing a real improvement, but also a weaker comparison base. This is not a footnote. It is exactly the kind of adjustment that can make the headline move look larger than the underlying economic change.

Sheret is already in proof mode, Bazel is still early

The second trigger is genuine project progress. Sheret is the more advanced asset, with 56 units sold out of 86 units for sale, targeted completion in the fourth quarter of 2026, and construction progress already around 70% at year-end and 77% near the report date. Bazel is a different story, 38 units sold out of 81, year-end construction progress of around 11%, and expected completion only in the fourth quarter of 2028. These projects are not saying the same thing. Sheret is a delivery and monetization test. Bazel is still a sales, pace and cost-discipline test.

The Dankner Kanlov deal changes scale, not certainty

The main trigger: on March 10, 2026, the company signed an agreement to acquire 50.8% of Dankner Kanlov Urban Renewal. The deal includes roughly NIS 14 million of secondary share purchases, NIS 25 million of capital injection and a subordinated shareholder loan of about NIS 5.2 million. In return, Intergama gains access to a company advancing 12 projects, with 344 units slated for evacuation and 571 units for sale at the company's share. That is a very fast jump from a platform with two projects to a platform that is materially broader.

But the problematic side should not be glossed over. Dankner Kanlov is not an acquisition of mature earnings. As of September 30, 2025 it reported NIS 14.435 million of revenue and a continuing-operations loss of NIS 2.489 million on a consolidated basis. Intergama also states explicitly that it cannot yet estimate the additional investment that may be required, and that public bond issuance is one possible future funding route. In other words, the deal expands the horizon, but what it buys today is mainly pipeline, organization and management, not cash flow.

The dividend says something about confidence, but also about priorities

During 2025 the company paid a cumulative NIS 2.045 million of dividends, and after the balance sheet date it approved another roughly NIS 1.03 million distribution. That signals confidence in the balance sheet, but it also reminds the reader that cash is still being pulled up while the development story is beginning to demand more capital. That is not necessarily the wrong decision, but it does highlight that the balance sheet is being asked to serve distribution, flexibility and strategic expansion at the same time.

Efficiency, Profitability and Competition

The income-producing assets remain the base, but not the growth engine

The income-producing segment delivered exactly what one would expect from it in 2025, stability, not breakout growth. Rental and management revenue rose just 1% to NIS 19.27 million, mainly because the leases are CPI linked. At the same time, cost of revenue rose 8% to NIS 5.259 million, largely because of higher building maintenance costs. The result was almost flat gross profit, NIS 14.01 million versus NIS 14.117 million in 2024, and a decline in gross margin for the yielding portfolio to 72.7% from 74.3%.

That is the heart of the current read. The yielding base still works, but it is no longer expanding margins. FFO attributable to shareholders also rose only modestly, to NIS 5.719 million from NIS 5.566 million in 2024. That is fine, but nowhere near enough on its own to explain why the company is interesting now.

Netanya improved, but even the appraiser does not call the cash flow stable

The good news is that Netanya is moving in the right direction. Occupancy rose to 85% at year-end 2025 from 80% a year earlier, and the asset's fair value rose to NIS 186.2 million from NIS 178.6 million. The appraiser also notes that effective occupancy across the marketable area is already 90%, up from 83% a year earlier, and that during 2025 the company signed new leases or exercised options covering 3,124 square meters of office space, 1,337 square meters of storage and 117 parking spaces.

But this is not a clean recovery. In the same valuation report the appraiser writes that expected office cash flow has improved but is still not stable, both because the area is less attractive for office use and because a meaningful amount of space has relatively short remaining lease terms. The appraiser also assumes a roughly two-year delay before vacant space is filled. So yes, the higher valuation is real, but it still rests on an improvement that needs to prove itself over time.

There is also a smaller but important warning sign. The tenant table excludes a roughly 791 square meter tenant that ran into financial difficulty, and in January 2026 its lease was extended only after a five-month rent concession, with two months at full discount and three months at a token NIS 5,000 per month. That is a useful clue. The Netanya market is better, but not yet strong enough for the company to harden terms against every tenant.

The signed-contract outlook is reasonable, but it also tells a story of stability rather than acceleration. Under the option-exercise scenario, expected fixed revenue for 2027 stands at NIS 20.135 million. Without option exercise, it drops to NIS 18.58 million. The gap is not huge, but it is a reminder that the improvement in Netanya still has to translate into longer and firmer lease visibility, not just better spot filling.

Herzliya moved from a wider planning canvas to a more conservative route

Herzliya tells the opposite story. Occupancy recovered to 98%, which is attractive, but fair value fell to NIS 101.4 million from NIS 108.6 million. The reason is not operating weakness. It is a reduction in the development scenario underpinning value. The company decided to move ahead independently and without the neighboring lot, so the valuation now assumes FAR 8 only rather than a broader consolidation scenario that could have supported more rights.

This is not just about long-dated blue-sky optionality. Herzliya also has a real licensing layer. The appraiser notes that around 746 square meters in the gallery level were built without a permit and assumes they can be regularized. So the Herzliya value is not simply a function of current rent and proximity to the planned light rail and metro. It also includes assumptions about the ability to regularize the current structure and keep advancing a new zoning plan. That makes the asset more of a planning option than a near-term earnings engine.

Residential profit looks large at the project level, but smaller once you climb to the listed company

The company is right to present the full project tables for Sheret and Bazel. On a 100% basis, the numbers are large, expected gross profit of NIS 96.734 million for Sheret and NIS 99.907 million for Bazel. Together that is NIS 196.641 million. But those are project-level numbers, not common-shareholder economics at the listed company.

Intergama's effective share in each project is about 16.67%. As a rough translation, that implies something in the area of NIS 33 million of future gross profit before headquarters, tax, financing and timing, and potentially a bit more because the company says its share of eventual surpluses should be slightly above its formal project share due to preferred shareholder-loan positioning. That is the key distinction. The value is there, but it does not flow one for one to listed shareholders, and certainly not at the pace the 100% tables might suggest.

Cash Flow, Debt and Capital Structure

The right cash view here is all-in cash flexibility

Because the central question is how much flexibility really remains ahead of the new acquisition, the right frame is all-in cash flexibility rather than a normalized cash-generation view. In that frame, the company generated NIS 9.116 million of operating cash flow in 2025. That is a good number, but it also included roughly NIS 1.3 million of tax refund. Then NIS 2.13 million went out through investing activity, and NIS 6.368 million went out through financing activity, which includes debt service, interest and dividends. The net cash change for the year was just NIS 618 thousand.

In other words, the business generates cash, but almost all of that cash is already being absorbed again. This is not a debt problem. It is a cushion problem. Cash at year-end was only NIS 1.146 million. Anyone looking only at NOI, FFO or book equity could miss how narrow the immediate cash buffer really is.

The balance sheet is strong, but the strength sits in assets more than in cash

And yet this is not a financially stressed company in the normal sense. Total liabilities fell to NIS 68.668 million, equity rose to NIS 258.437 million, and debt to fair value of assets fell to just 4%, compared with 6% in 2024 and 24% in 2023. Financial debt against the yielding assets is only NIS 11.377 million, and the Netanya asset, worth NIS 186.2 million, is unencumbered. So Intergama's flexibility does not come from cash on hand. It comes from balance-sheet quality and the ability to layer more financing onto that balance sheet if needed.

That tension matters. On one side, the balance sheet gives the company room to act. On the other side, any larger move now pushes it quickly from a story of conservatism toward a story of balance-sheet deployment. That is exactly what the Dankner Kanlov deal is about.

The Dankner Kanlov deal will be judged through funding first

The company says explicitly that it intends to finance the acquisition from its own resources and with a bank loan, and that it is reviewing several financing proposals. That is an important admission. The deal is not closed yet, the initial commitment alone is around NIS 45 million, and on top of that there is a framework for up to NIS 10 million of shareholder loans over three years, while the other shareholders are supposed to match 50% of each actual draw.

So the market will not test only whether the asset pipeline is attractive. It will first test whether the financing structure leaves enough breathing room after completion. Put differently, up through 2025 the company benefited from very low leverage. After the deal, it will be judged on how it chooses to use that advantage.

Forward Look

Before getting into the details, these are the four points that matter most for the next year:

• 2026 looks less like a breakout year and more like a proof-and-funding year. The projects need to keep moving, but the market will look first at capital sources.
• Sheret is now close enough to start converting execution into profit that feels tangible, while Bazel is still far enough away to remain more exposed to sales and cost surprises.
• Herzliya remains an important planning option, but not a near-term catalyst. The benefit there will come if and when zoning clarity improves, not from the current rental stream itself.
• The yielding portfolio is unlikely to surprise strongly enough on its own. If the market's read changes, it will probably be because the residential projects monetize better and the new expansion is financed in an orderly way.

Sheret is the near-term proof project

Sheret is the most important development asset for the 2026 read. On a 100% basis it includes 86 units for sale, 56 of which were already sold, expected completion in the fourth quarter of 2026, and expected gross profit of NIS 96.734 million. What matters is not just the size of those numbers, but the phase the project is in. This is no longer a planning story. It is an execution story, with high completion, signed contracts and an approaching delivery test.

In market terms, Sheret can change the tone around the company if it proves three things together, delivery timing holds, expected margin does not erode materially, and project surplus can actually start moving upward without getting trapped in financing layers. If one of those three cracks, even an advanced project can suddenly look less compelling.

Bazel is a test of demand, pace and cost

Bazel differs from Sheret in almost every way that matters for the market. Thirty-eight units have been sold out of 81, completion is expected only in the fourth quarter of 2028, and year-end construction progress was around 11%. On the positive side, the project carries expected gross profit of NIS 99.907 million and a bank financing framework of NIS 1.186 billion. On the other hand, precisely because the project is younger, a larger share of the value still depends on future sales, future construction cost and the rate-demand backdrop.

So Bazel is not a one-quarter catalyst. It is a two-year test. If sales stay reasonable and execution advances without a sharp cost jump, it can turn the 100% tables into something more tangible. If not, it will remain mostly pipeline on paper.

Herzliya is potential, not a near-term engine

In Herzliya the company keeps talking about asset enhancement through zoning work and a mixed-use tower. That can clearly be value creating. But as of year-end 2025 the valuation already reflects a narrower independent scenario, with FAR 8 only and total rights of roughly 16 thousand square meters. This is not the place to build a near-term catalyst case. It is an asset with optionality, not a two-year cash engine.

That distinction matters, because it is easy to look at the planned light rail, metro proximity and wider area renewal and tell yourself a quick rerating story. In practice, the valuation was already marked down once the company chose the more conservative route, and future progress still depends on planning decisions the company does not control on its own.

Dankner Kanlov can change scale, but also the risk profile

If the next year needs a name, it is a transition year from a small holding structure to a broader development platform. The Dankner Kanlov acquisition can increase activity scale, deepen urban-renewal exposure and bring in a 12-project platform instead of just two projects. That is a real step up.

But it also adds practical friction. Conditions precedent had not yet been completed when the accounts were approved. Management fees are built in for the acquired company's CEO, for companies controlled by the other shareholders and for Intergama itself. Certain shareholders get veto rights above specific ownership thresholds. And there is a 30-month valuation-adjustment mechanism if projects fail. None of these points kills the deal, but together they mean this transaction is not only adding pipeline. It is also adding a governance layer, incentive complexity and execution burden.

Risks

Funding risk comes before debt risk

The main risk right now is not that the company is already overleveraged. It is that it is about to move quickly from a conservative balance sheet to one that must fund a strategic jump. That is a material difference. As long as the Dankner Kanlov deal is not closed, flexibility looks high. Once it closes, the real question becomes how much room remains after the initial commitment, after shareholder-loan frameworks, and after the extra capital needs the company itself says it still cannot estimate.

Development profit can look great on paper and still erode on the way to cash

The company itself classifies weaker housing demand and higher execution costs as high-impact risks. That is not generic boilerplate. It is exactly the link between the attractive Sheret and Bazel tables and the profit that will eventually arrive. Any delay, cost jump, sales slowdown or softer commercial terms can hit margin, burden working capital and push project surplus further out.

Even the yielding portfolio carries quality risk, not just occupancy risk

In the office and logistics assets, the risk is not only whether space gets leased, but on what terms. In Netanya we already saw that the occupancy improvement still required commercial flexibility. In Herzliya we saw that value depends on planning and licensing assumptions. So the base assets are good, but not immune. They simply look safer relative to the development risk being built on top of them.

Governance and related-party exposure still deserve attention

The controlling shareholder owns 83.78% of the company, the CEO is his daughter, and related parties are present both as tenants and as service providers. Aggregate rent income from related parties reached NIS 2.018 million in 2025. The company notes that in 2025 no single customer accounted for more than 10% of revenue, but concentration of control and related-party links remain part of the story. The Dankner Kanlov deal also adds a layer of management fees and veto rights. None of this is unusual for the market, but it is still embedded friction worth watching.

Conclusions

Intergama exits 2025 as a stronger operating company than the first read suggests, but also a more complex one. The yielding assets still provide a reasonable base, leverage is low, and Sheret is already approaching the point where development profit should start to look more tangible. On the other hand, the market is unlikely to give much credit for pipeline and appraisals unless it sees orderly funding, consistent sales and gradual conversion of accounting value into real cash.

Current thesis: Intergama is no longer just a small asset holder, but a real-estate company using yielding assets to fund a gradual but real transition into a broader urban-renewal platform.

What changed versus the earlier read: In 2025 the center of gravity genuinely shifted away from the office assets and toward the development pipeline. Not because the yielding assets deteriorated sharply, but because future profit, expansion appetite and the market's likely triggers now sit mainly in Sheret, Bazel and Dankner Kanlov.

Best counter-thesis: All of that development value may remain too slow, too leveraged and too theoretical, while the company in practice still depends on two modest assets and on a barely tradable stock, so the gap between value on paper and value accessible to shareholders can remain open for a long time.

What could change the market's read in the short to medium term: closing and financing the new deal, actual entry of signed tenants into Netanya, continued sales in Bazel, and Sheret moving closer to delivery without material cost slippage.

Why this matters: This is a company sitting exactly at the point where balance-sheet quality gives it room to take more risk in order to build a new growth engine. If that works, the business profile changes. If it is done too aggressively, the company's main advantage, conservative balance-sheet positioning, starts to erode.

What must happen over the next 2-4 quarters for the thesis to strengthen: Sheret has to stay on a clean delivery path, Bazel has to keep selling and building, Dankner Kanlov has to close on a reasonable funding structure, and Netanya has to show that better occupancy is translating into more stable rent quality. What would weaken the thesis is some combination of heavier-than-expected financing, softer project selling terms or further value updates that depend more on assumptions than on execution.